We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Coronavirus crisis has dealt a blow to the broader investing world, pushing Wall Street into a bear market territory. But one zone that performed worse even during the rosier times, seems to be bouncing back in this difficult phase. That area is marijuana.
It’s been a volatile journey for marijuana stocks in the past year. Earnings weakness, regulatory issues, “longer-than-anticipated product rollouts and overly enthusiastic forward estimates” hit the space hard.
Pure-play marijuana fund ETFMG Alternative Harvest ETF (MJ - Free Report) has plunged 67.3% in the past year, shed 29.3% this year so far and declined 19.4% in the past month. However, the fund gained 9.4% on Mar 26. What made this surge possible?
Rationale Behind the Recent Rally
Regulatory backdrop holds the wild card for the industry’s well-being.Most Democrats have recommended marijuana legalization in their campaign. However, Republicans are yet to give a green signal. Donald Trump has not given any clue about his preference on the legalization of marijuana but senior Republican leaders are not quite supportive of marijuana legalization unlike Democratic leaders, per Market Realist (read: What's Ahead for Marijuana ETFs After a Dismal Show in 2019?).
Analysts are now of the view that the United States may now be forced to give a nod to the recreational marijuana selling to cover up some of the massive economic damages caused by the coronavirus pandemic. DataTrek Research’s Jessica Rabe writes in a note, “there’s a simple and effective solution for states and cities to help cover their huge budget shortfalls after the COVID-19 pandemic subsides: legalize recreational sales of marijuana,” as quoted on yahoo finance.
Sales have also been strong for marijuana amid the latest virus outbreak. “Between the time period of March 16 and March 22, key US markets, including California, Colorado, Oregon and Alaska experienced a 50 percent rise in sales of recreational cannabis, and a 41 percent rise in medical cannabis sales from the same period last year”, per a cannabishealthinsider.com article. Cannabis dispensaries have been listed as “essential services” along with other health facilities (read: What Do Canopy Earnings Say About Cannabis ETFs?).
Any Wall of Worry?
Per a CNBC article, “one of the big concerns is whether cannabis businesses that have to close and send employees home will have to continue paying them under a new federal law, the Families First Coronavirus Response Act. The businesses may not qualify for federal aid in return since marijuana remains federally illegal.” So, even if sales are soaring now, the bottom line may be stressful for these companies.
Stocks and ETFs in Focus
Canopy Growth (CGC - Free Report) (up 8.4% on Mar 26) has a Zacks Rank #2 (Buy) and it came from a favorable Zacks industry (top 20%). Tilray Inc. (TLRY - Free Report) (up 56.8%) belongs to a favorable Zacks industry (top 18%) though it has a Zacks Rank #4 (Sell). Aphria Inc. (APH - Free Report) A) (up 13.3%) has a Zacks Rank of 3 and hails from a favorable Zacks industry (top 20%).
Given the ongoing scenario, investors can keep close tabs on marijuana ETFs like AdvisorShares Pure Cannabis ETF (YOLO - Free Report) (up 9.8% on Mar 26), Cambria Cannabis ETF (TOKE - Free Report) (up 8.4% on Mar 26),Amplify Seymour Cannabis ETF (CNBS - Free Report) (up 8.2%), Cannabis ETF (up 11.1% on Mar 26) and Global X Cannabis ETF (up 11.8%).
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Marijuana Stocks & ETFs Coronavirus-Proof?
Coronavirus crisis has dealt a blow to the broader investing world, pushing Wall Street into a bear market territory. But one zone that performed worse even during the rosier times, seems to be bouncing back in this difficult phase. That area is marijuana.
It’s been a volatile journey for marijuana stocks in the past year. Earnings weakness, regulatory issues, “longer-than-anticipated product rollouts and overly enthusiastic forward estimates” hit the space hard.
Pure-play marijuana fund ETFMG Alternative Harvest ETF (MJ - Free Report) has plunged 67.3% in the past year, shed 29.3% this year so far and declined 19.4% in the past month. However, the fund gained 9.4% on Mar 26. What made this surge possible?
Rationale Behind the Recent Rally
Regulatory backdrop holds the wild card for the industry’s well-being.Most Democrats have recommended marijuana legalization in their campaign. However, Republicans are yet to give a green signal. Donald Trump has not given any clue about his preference on the legalization of marijuana but senior Republican leaders are not quite supportive of marijuana legalization unlike Democratic leaders, per Market Realist (read: What's Ahead for Marijuana ETFs After a Dismal Show in 2019?).
Analysts are now of the view that the United States may now be forced to give a nod to the recreational marijuana selling to cover up some of the massive economic damages caused by the coronavirus pandemic. DataTrek Research’s Jessica Rabe writes in a note, “there’s a simple and effective solution for states and cities to help cover their huge budget shortfalls after the COVID-19 pandemic subsides: legalize recreational sales of marijuana,” as quoted on yahoo finance.
Sales have also been strong for marijuana amid the latest virus outbreak. “Between the time period of March 16 and March 22, key US markets, including California, Colorado, Oregon and Alaska experienced a 50 percent rise in sales of recreational cannabis, and a 41 percent rise in medical cannabis sales from the same period last year”, per a cannabishealthinsider.com article. Cannabis dispensaries have been listed as “essential services” along with other health facilities (read: What Do Canopy Earnings Say About Cannabis ETFs?).
Any Wall of Worry?
Per a CNBC article, “one of the big concerns is whether cannabis businesses that have to close and send employees home will have to continue paying them under a new federal law, the Families First Coronavirus Response Act. The businesses may not qualify for federal aid in return since marijuana remains federally illegal.” So, even if sales are soaring now, the bottom line may be stressful for these companies.
Stocks and ETFs in Focus
Canopy Growth (CGC - Free Report) (up 8.4% on Mar 26) has a Zacks Rank #2 (Buy) and it came from a favorable Zacks industry (top 20%). Tilray Inc. (TLRY - Free Report) (up 56.8%) belongs to a favorable Zacks industry (top 18%) though it has a Zacks Rank #4 (Sell). Aphria Inc. (APH - Free Report) A) (up 13.3%) has a Zacks Rank of 3 and hails from a favorable Zacks industry (top 20%).
Given the ongoing scenario, investors can keep close tabs on marijuana ETFs like AdvisorShares Pure Cannabis ETF (YOLO - Free Report) (up 9.8% on Mar 26), Cambria Cannabis ETF (TOKE - Free Report) (up 8.4% on Mar 26),Amplify Seymour Cannabis ETF (CNBS - Free Report) (up 8.2%), Cannabis ETF (up 11.1% on Mar 26) and Global X Cannabis ETF (up 11.8%).
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>